View in EDS

A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.

Saved in:
Bibliographic Details
Title: A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.
Authors: Lynce F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Graham N; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kochupurakkal BS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Nguyen H; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Bychkovsky B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Poorvu PD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Attaya V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Davis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., DiLullo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., D'Andrea AD; Harvard Medical School, Boston, Massachusetts.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Garber JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts., Garg K; Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin., Lim LP; Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin., Li M; Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin., Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tayob N; Harvard Medical School, Boston, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Feb 04; Vol. 32 (3), pp. 489-500.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41335237
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lynce+F%22">Lynce F</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Graham+N%22">Graham N</searchLink>; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Kochupurakkal+BS%22">Kochupurakkal BS</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Nguyen+H%22">Nguyen H</searchLink>; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Bychkovsky+B%22">Bychkovsky B</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Poorvu+PD%22">Poorvu PD</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Attaya+V%22">Attaya V</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Davis+R%22">Davis R</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22DiLullo+M%22">DiLullo M</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22D'Andrea+AD%22">D'Andrea AD</searchLink>; Harvard Medical School, Boston, Massachusetts.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Garber+JE%22">Garber JE</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Garg+K%22">Garg K</searchLink>; Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Lim+LP%22">Lim LP</searchLink>; Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; Resolution Bioscience (now a part of Exact Sciences), Madison, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Paweletz+CP%22">Paweletz CP</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Tayob+N%22">Tayob N</searchLink>; Harvard Medical School, Boston, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2026 Feb 04; Vol. 32 (3), pp. 489-500.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41335237
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-25-0571
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 489
    Titles:
      – TitleFull: A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lynce F
      – PersonEntity:
          Name:
            NameFull: Graham N
      – PersonEntity:
          Name:
            NameFull: Kochupurakkal BS
      – PersonEntity:
          Name:
            NameFull: Nguyen H
      – PersonEntity:
          Name:
            NameFull: Bychkovsky B
      – PersonEntity:
          Name:
            NameFull: Poorvu PD
      – PersonEntity:
          Name:
            NameFull: Attaya V
      – PersonEntity:
          Name:
            NameFull: Davis R
      – PersonEntity:
          Name:
            NameFull: DiLullo M
      – PersonEntity:
          Name:
            NameFull: D'Andrea AD
      – PersonEntity:
          Name:
            NameFull: Garber JE
      – PersonEntity:
          Name:
            NameFull: Garg K
      – PersonEntity:
          Name:
            NameFull: Lim LP
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Paweletz CP
      – PersonEntity:
          Name:
            NameFull: Tayob N
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 02
              Text: 2026 Feb 04
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 32
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1